acut
graftversushost
diseas
agvhd
major
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
system
steroid
treatment
repres
firstlin
therapi
agvhd
associ
respons
rate
steroidresist
patient
poor
prognosi
high
transplantationrel
mortal
trm
sever
secondlin
therapi
propos
manag
unrespons
agvhd
without
proven
benefici
effect
patient
outcom
overal
longterm
surviv
reason
extracorpor
photochemotherapyphotopheresi
ecp
cellbas
approach
control
gvhd
spare
gener
immunosuppress
seem
promis
studi
report
outcom
consecut
pediatr
patient
treat
ecp
agvhd
among
patient
steroidresist
agvhd
steroiddepend
agvhd
receiv
steroid
firstlin
therapi
clinic
contraind
complet
respons
obtain
patient
partial
respons
observ
respons
patient
day
trm
whole
cohort
trm
among
respond
nonrespond
ecp
respect
p
overal
surviv
show
differ
respond
nonrespond
respect
p
time
progress
primari
diseas
without
signific
differ
group
moreov
progressionfre
surviv
primari
diseas
signific
differ
p
respond
nonrespond
ecp
conclus
studi
demonstr
ecp
highli
effect
agvhd
without
neg
impact
primari
diseas
allogen
allo
hematopoiet
stem
cell
transplant
hsct
increasingli
use
therapeut
approach
hematolog
nonhematolog
diseas
last
decad
improv
infect
monitor
prophylaxi
immunosuppress
strategi
highresolut
hla
type
support
care
measur
led
better
outcom
procedur
despit
advanc
acut
graftversushost
diseas
agvhd
remain
major
caus
morbid
mortal
allohsct
standard
diagnosi
manag
agvhd
british
guidelin
publish
joint
work
group
british
committe
standard
haematolog
british
societi
bone
marrow
transplant
document
includ
recommend
diagnosi
manag
agvhd
well
primari
treatment
option
patient
steroidrefractori
sr
diseas
standard
manag
agvhd
includ
steroid
differ
dose
depend
agvhd
grade
improv
agvhd
day
note
progress
within
hour
observ
addit
secondlin
agent
consid
secondlin
option
mycophenol
mofetil
mmf
antitnf
antibodi
mammalian
target
rapamycin
inhibitor
receptor
antibodi
extracorpor
photochemotherapyphotopheresi
ecp
unfortun
despit
multipl
clinic
trial
singl
agent
improv
overal
surviv
os
patient
fail
steroid
treatment
identifi
moreov
current
surviv
year
patient
respond
steroid
versu
nonrespond
nr
shown
transplantationrel
mortal
trm
higher
steroidresist
patient
studi
focus
ecp
one
promis
treatment
agvhd
briefli
ecp
consist
procedur
collect
peripher
leukocyt
cell
irradi
cell
ultraviolet
light
presenc
reinfus
treat
cell
patient
underli
mechan
action
ecp
gvhd
complet
understood
within
hour
process
induc
apoptosi
treat
cell
includ
cell
subsequ
phagocytosi
antigenpres
cell
result
might
regul
immun
homoeostasi
modul
cytokin
product
induc
toler
antigenpres
cell
ecp
demonstr
effect
treat
steroidresist
steroiddepend
patient
agvhd
pediatr
set
particular
report
respons
rate
rang
accord
organ
involv
agvhd
steroidresist
patient
year
os
significantli
increas
complet
respond
ecp
compar
nr
italian
societi
haemapheresi
cell
manipul
italian
group
bone
marrow
transplant
elabor
best
practic
recommend
ecp
reflect
common
clinic
practic
italian
transplant
center
ecp
perform
total
procedur
per
year
despit
larg
use
ecp
publish
report
deal
retrospect
data
difficult
compar
patient
select
criteria
treatment
schedul
patient
monitor
patient
assess
protocol
differ
among
institut
moreov
random
studi
conduct
patient
agvhd
report
singlecent
experi
ecp
treatment
pediatr
patient
agvhd
respons
ecp
trm
os
progressionfre
surviv
pf
primari
diseas
time
progress
ttp
primari
diseas
patient
treat
ecp
analyz
januari
june
consecut
pediatr
patient
male
femal
affect
agvhd
treat
ecp
hsct
unit
univers
hospit
padova
fifteen
patient
previous
report
clinic
characterist
patient
shown
tabl
median
age
ecp
year
rang
year
median
bodi
weight
kg
rang
kg
fifteen
children
weight
less
kg
last
followup
fix
june
detail
patient
treat
ecp
agvhd
refractori
steroid
defin
progress
improv
agvhd
least
day
day
methylprednisolon
mp
mgkg
bodi
weight
respect
sr
group
patient
steroiddepend
agvhd
defin
flareup
agvhd
taper
mp
sd
group
children
agvhd
requir
reduct
pharmacolog
contraind
therapi
viral
reactiv
system
mycos
intoler
side
effect
group
infecti
complic
ic
particular
patient
ic
group
ica
group
underw
ecp
without
steroid
firstlin
therapi
contraind
tcr
ab
haploident
transplant
probabl
invas
pulmonari
aspergillosi
ipa
adenoviru
adv
proven
ipa
concomit
prove
ipa
cytomegaloviru
cmv
reactiv
probabl
ipa
cmv
bk
viru
bkv
reactiv
proven
ipa
multipl
viral
reactiv
includ
adv
cmv
epsteinbarr
viru
ebv
cmv
reactiv
cmv
ebv
reactiv
cmv
ebv
adv
bkv
reactiv
patient
icb
group
sd
agvhd
cyclosporin
csa
erel
renal
insuffici
patient
sd
agvhd
concomit
infect
remain
patient
cmv
reactiv
cmv
ebv
reactiv
cmv
bkv
reactiv
cmv
adv
bkv
reactiv
ebv
reactiv
ebv
adv
reactiv
ebv
reactiv
probabl
aspergillosi
hepat
b
viru
hepat
b
viru
ebv
reactiv
cmv
ebv
bkv
reactiv
adv
human
bkv
coronaviru
hepat
c
viru
cmv
proven
ipa
n
practic
surveil
viral
fungal
infect
blood
routin
perform
first
day
hsct
patient
includ
ebvdna
cmvdna
advdna
human
dna
bkvdna
jcdna
galactomannan
antigen
search
schedul
perform
week
allohsct
recipi
hlaident
sibl
twice
week
allohsct
recipi
unrel
haploident
donor
monitor
viral
infect
urin
compris
cmvdna
bkvdna
jcvdna
weekli
search
blood
urin
stool
cultur
nasal
throat
swab
nasopharyng
aspir
weekli
perform
search
virus
microbiolog
agent
perform
upon
clinic
symptom
viral
reactiv
detect
pcr
posit
ebvdna
cutoff
copiesml
cmvdna
cutoff
copi
ml
advdna
qualit
test
clinic
system
fungal
infect
defin
prove
probabl
accord
european
organ
research
treatment
cancer
criteria
cutoff
galactomannan
index
set
enzym
immuno
assay
eia
method
algorithm
agvhd
treatment
use
center
shown
figur
csa
administ
month
children
receiv
hsct
hlaident
sibl
unrel
donor
respect
unrel
hsct
shortterm
methotrex
rabbit
antithymocyt
globulin
atg
given
unrel
cord
blood
hsct
prophylaxi
includ
csa
atg
haploident
set
ex
vivo
elimin
ab
cell
b
cell
done
atg
administ
cell
infus
therapi
given
hsct
inform
consent
obtain
patient
parent
well
patient
possibl
use
ecp
approv
ethic
committe
hospit
padova
clinic
organ
involv
grade
combin
obtain
overal
grade
accord
glucksberg
criteria
agvhd
histolog
confirm
obtain
whenev
clinic
indic
confirm
gvhd
diagnosi
elig
criteria
ecp
treatment
follow
children
sr
agvhd
n
children
sd
agvhd
n
patient
agvhd
therapi
contraind
requir
rapid
decreas
therapi
increas
ebv
viral
load
cmv
reactiv
subsequ
sampl
system
fungal
infect
intoler
side
effect
n
children
must
present
complet
hematolog
remiss
full
donor
chimer
white
blood
cell
wbc
count
l
concomit
treatment
either
atg
monoclon
antibodi
ecp
perform
use
differ
techniqu
inlin
treatment
uvar
photopheresi
instrument
therako
exton
pa
use
patient
offlin
techniqu
cobe
spectra
bct
terumo
lakewood
co
use
children
technic
descript
alreadi
publish
offlin
techniqu
introduc
treat
lowweight
children
patient
weigh
less
kg
prime
leukapheresi
circuit
irradi
leukoreduc
red
blood
cell
regardless
baselin
hemoglobin
level
perform
recommend
italian
societi
haemapheresi
cell
manipulationitalian
group
bone
marrow
transplant
indic
preecp
hemoglobin
level
maintain
gdl
gdl
cell
product
treat
dilut
final
concentr
ml
mg
ml
accord
specif
procedur
inlin
techniqu
ml
offlin
techniqu
ml
patient
french
hickman
doublelumen
central
cathet
systemat
use
procedur
provid
adequ
flow
rate
ie
mlkgminut
anticoagul
urokinas
u
hour
locktherapi
perform
day
procedur
leukapheresi
product
contain
median
wbc
ul
rang
median
mononuclear
cell
mnc
rang
median
number
wbc
reinfus
patient
rang
wherea
median
number
mnc
reinfus
patient
rang
patient
treat
ecp
twice
week
first
month
everi
week
second
third
month
monthli
least
month
total
procedur
progress
taper
discontinu
ecp
decid
upon
evalu
individu
respons
concomit
therapi
initi
maintain
modifi
discontinu
accord
clinic
respons
criteria
defin
respons
ecp
previous
report
patient
enrol
ecp
day
includ
group
respons
ecp
evalu
day
day
end
ecp
treatment
complet
respons
cr
defin
resolut
sign
agvhd
partial
respons
pr
least
improv
clinic
sign
latter
case
given
complex
assess
respons
defin
pr
organ
follow
skin
least
reduct
bodi
surfac
area
affect
gi
tract
liver
reduct
volum
diarrhea
valu
bilirubin
worsen
organ
involv
well
appear
new
sign
symptom
gvhd
defin
progress
diseas
pd
patient
stabl
pd
consid
nr
seventytwo
consecut
patient
agvhd
receiv
ecp
median
time
day
rang
hsct
day
rang
diagnosi
agvhd
sixtyfour
patient
skin
involv
grade
iv
n
grade
iii
n
grade
ii
n
grade
n
fiftyf
patient
gastrointestin
gi
agvhd
grade
iv
n
grade
iii
n
grade
ii
n
grade
n
twelv
patient
liver
involv
grade
iii
n
grade
ii
n
grade
n
regard
number
organ
involv
patient
skin
affect
present
gi
involv
wherea
patient
combin
skin
gi
agvhd
patient
combin
gi
liver
agvhd
patient
combin
skin
gi
liver
agvhd
ica
group
infecti
complic
steroid
ecp
icb
group
infecti
complic
steroid
ecp
hla
match
consid
overal
clinic
grade
agvhd
follow
grade
n
grade
ii
n
grade
iii
n
grade
iv
n
detail
differ
grade
patient
subgroup
found
tabl
clinic
evalu
patient
conduct
everi
ecp
procedur
sixtythre
patient
agvhd
grade
iv
receiv
mgkg
day
mp
firstlin
therapi
median
dose
steroid
begin
ecp
mgkgday
detail
therapi
ecp
csa
n
csa
plu
steroid
mgkg
n
tacrolimu
plu
steroid
mgkg
n
csa
tacrolimu
plu
mmf
plu
steroid
n
ecp
use
firstlin
therapi
patient
second
line
therapi
patient
among
haploident
hsct
treat
csa
thirdlin
patient
patient
fourthlin
therapi
patient
characterist
compar
use
chisquar
fisher
exact
test
appropri
case
discret
variabl
mannwhitney
test
case
continu
variabl
trm
calcul
date
hsct
day
last
followup
consid
event
nonrelaps
caus
death
os
calcul
date
hsct
date
death
caus
last
followup
pf
calcul
date
hsct
date
relaps
underli
primari
diseas
death
caus
last
followup
ttp
calcul
date
hsct
date
relaps
primari
diseas
last
follow
cumul
incid
ci
relaps
underli
diseas
estim
compet
risk
model
consid
death
caus
cgvhd
compet
event
surviv
analysi
perform
use
kaplanmei
method
confid
interv
standard
error
se
surviv
incid
rate
given
differ
group
compar
use
logrank
test
gray
test
report
p
valu
statist
signific
set
sa
institut
cari
nc
releas
respons
ecp
treatment
evalu
accord
overal
grade
agvhd
organ
involv
day
day
end
ecp
summar
tabl
end
treatment
ecp
patient
cr
pr
nr
among
patient
show
cr
patient
agvhd
grade
patient
grade
ii
grade
iii
grade
iv
particular
cr
rate
patient
agvhd
grade
ii
grade
iii
iv
respect
p
wherea
pr
rate
patient
agvhd
grade
ii
grade
ii
iv
respect
p
signific
statist
differ
cr
rate
observ
accord
subgroup
analyz
sr
sd
ic
group
p
ecp
discontinu
cr
agvhd
manifest
skin
gut
liver
observ
patient
respect
maxim
respons
ecp
observ
week
treatment
procedur
result
ecp
end
treatment
possibl
discontinu
therapi
patient
reduc
patient
receiv
allohsct
unrel
donor
regard
steroid
taper
patient
treat
mgkgday
ecp
steroid
dose
reduc
month
ecp
treatment
month
month
ecp
treatment
median
lanskykarnofski
perform
score
improv
ecp
complet
treatment
associ
found
respond
nr
ecp
major
clinic
risk
factor
affect
agvhd
tabl
cgvhd
twentythre
patient
present
clinic
manifest
cgvhd
tabl
detail
patient
progress
cgvhd
nr
pr
ecp
patient
quiescent
cgvhd
onset
median
month
rang
day
month
end
ecp
overal
grade
cgvhd
base
nation
institut
health
consensu
mild
patient
moder
patient
sever
patient
among
patient
progress
cgvhd
ecp
use
therapi
patient
obtain
cr
overal
patient
aliv
last
followup
cgvhd
discontinu
therapi
wherea
patient
present
cgvhd
still
treatment
patient
quiescent
cgvhd
aliv
last
followup
patient
free
cgvhd
without
therapi
patient
cgvhd
still
treatment
therapi
plu
ecp
associ
found
respond
nr
ecp
onset
quiescent
cgvhd
day
overal
trm
se
trm
se
se
respond
nr
ecp
respect
p
last
followup
overal
trm
se
wherea
trm
stratifi
respond
nr
se
se
respect
p
figur
b
os
se
statist
signific
differ
respond
nr
se
versu
se
respect
p
figur
b
pf
primari
diseas
group
se
signific
differ
p
respond
se
nr
se
figur
b
overal
ttp
primari
diseas
se
without
signific
differ
group
respond
se
versu
nr
se
p
figur
b
compar
patient
surviv
rate
ecp
treatment
use
first
second
thirdfourthlin
therapi
differ
observ
respond
nr
term
os
p
pf
p
ttp
p
overal
ci
relaps
underli
diseas
se
particular
se
se
respond
nr
ecp
respect
figur
b
overal
last
followup
median
time
hsct
year
rang
year
patient
aliv
without
gvhd
without
therapi
twentyon
patient
die
relaps
primari
diseas
nrm
among
last
group
patient
agvhd
die
day
hsct
sepsi
patient
cgvhd
die
cmv
pneumonia
case
acut
hepat
hcv
infect
case
encephalopathi
case
multiorgan
failur
case
patient
die
cmv
pneumonia
day
hsct
without
evid
cgvhd
side
effect
observ
ecp
gener
mild
frequent
lowweight
children
ecp
caus
mild
hypotens
patient
associ
abdomin
pain
case
episod
apheresi
session
advers
effect
warrant
suspend
procedur
transient
reduct
hemoglobin
platelet
andor
wbc
count
ecp
treatment
like
independ
posttransplant
cours
put
ecprel
observ
patient
respect
one
patient
grade
iv
agvhd
highdos
steroid
therapi
mgkg
day
experienc
acut
gi
bleed
second
cours
ecp
gi
endoscopi
show
multipl
ulcer
stomach
girl
preexist
cardiac
impair
show
acut
heart
failur
fluid
overload
procedur
quickli
respond
adequ
therapi
one
girl
ecp
procedur
anaphylaxi
cough
vomit
abdomin
pain
hypotens
palpebr
edema
minut
end
irradi
bag
infus
respond
antihistamin
steroid
therapi
ecp
treatment
stop
aim
retrospect
studi
analyz
role
ecp
treatment
agvhd
efficaci
ecp
well
establish
treatment
cgvhd
wherea
agvhd
prospect
random
studi
publish
howev
use
ecp
suggest
secondlin
therapi
togeth
mammalian
target
rapamycin
inhibitor
mmf
receptor
antibodi
antitnf
antibodi
largest
phase
prospect
studi
explor
feasibl
efficaci
ecp
treatment
agvhd
adult
involv
patient
perform
greinix
et
al
report
cr
rate
skin
liver
gi
agvhd
far
data
pediatr
patient
treat
ecp
agvhd
report
show
overal
cr
rate
rang
surviv
rate
rang
date
largest
pediatr
case
seri
treat
singl
center
sampl
size
found
higher
overal
respons
rate
ecp
compar
multicent
retrospect
studi
italian
associ
pediatr
hematologyoncolog
aieop
versu
attempt
determin
factor
may
influenc
observ
higher
respons
last
year
mani
chang
introduc
hsct
highresolut
hla
type
new
agent
condit
regimen
use
atg
monoclon
antibodi
new
antifung
drug
difficult
determin
modif
may
influenc
outcom
could
also
hypothes
specif
expertis
pediatr
hsct
earlier
treatment
ecp
day
seri
versu
day
aeiop
studi
may
improv
overal
outcom
studi
need
address
topic
associ
found
respond
nr
set
ecp
major
risk
factor
agvhd
addit
seri
differ
found
accord
grade
gvhd
grade
ii
versu
grade
iii
iv
p
subgroup
patient
analyz
sr
sd
ic
p
result
show
better
respons
rate
report
literatur
advanc
stage
diseas
higher
grade
poorer
respons
therapi
correl
worst
outcom
nevertheless
higher
cr
rate
observ
grade
ii
gvhd
suggest
earli
start
ecp
session
may
benefici
even
studi
time
start
ecp
versu
day
influenc
respons
group
ecp
seem
effect
involv
organ
previous
report
result
support
ecp
steroidspar
treatment
fact
steroid
dose
reduc
month
respect
onset
ecp
perform
ecp
frontlin
therapi
patient
fungal
infect
viral
reactiv
agvhd
complet
respons
knowledg
first
report
ecp
firstlin
treatment
therapi
either
discontinu
reduc
respond
patient
well
known
literatur
therapi
increas
risk
infecti
complic
relaps
underli
diseas
allohsct
children
may
particularli
vulner
consequ
gvhd
prolong
treatment
agent
use
ecp
particularli
appeal
efficaci
ecp
control
gvhd
affect
preserv
graftversusleukemia
effect
fact
low
incid
relaps
underli
diseas
record
us
other
mani
concern
rais
relat
technic
aspect
apheresi
pediatr
set
children
low
bodi
weight
caregiv
care
monitor
patient
sign
symptom
hypovolemia
experi
ecp
well
toler
mild
advers
effect
frequent
mild
hypotens
abdomin
pain
headach
curious
symptom
record
often
ecp
compar
apheret
procedur
major
side
effect
observ
earliest
period
ecp
perform
center
observ
support
idea
learn
process
manag
technic
element
side
effect
experi
ecp
feasibl
even
young
children
low
bodi
weight
kg
technic
perform
prime
circuit
irradi
leukodeplet
red
blood
cell
regardless
baselin
hemoglobin
level
author
recent
report
salin
infus
albumin
bolus
may
altern
prime
approach
patient
bodi
weight
rang
kg
howev
proven
approach
could
safe
transfer
popul
weight
less
kg
current
use
ecp
techniqu
includ
offlin
inlin
devic
center
techniqu
use
differ
time
period
differ
respons
rate
observ
number
wbc
collect
mnc
reinfus
affect
clinic
outcom
notabl
patient
underw
procedur
bilumen
central
venou
line
alreadi
place
hickmanbroviac
bard
access
system
salt
lake
citi
ut
usa
differ
major
report
larger
central
venou
line
instanc
quinton
place
would
interest
extend
experi
determin
urokinas
anticoagul
allow
proper
flow
rate
preexist
central
venou
line
experi
staff
complet
procedur
patient
requir
sedat
ci
cgvhd
pediatr
popul
rang
accord
sourc
stem
cell
hlaident
sibl
cord
blood
versu
match
unrel
donor
peripher
blood
wherea
aieop
experi
ci
cgvhd
report
small
seri
incid
cgvhd
major
children
present
progress
cgvhd
quiescent
cgvhd
reason
hard
determin
patient
previous
treat
ecp
agvhd
could
benefit
retreat
data
consist
literatur
result
encourag
us
exploit
promis
approach
agvhd
conclus
standard
approach
ecp
treatment
need
pediatr
patient
perspect
share
singlecent
experi
great
valu
build
experi
howev
time
propos
random
prospect
trial
